R-CHOP protocol: Clinical Trials

42 trials of R-CHOP protocol, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

12 unknown, 10 completed, 9 active not recruiting, 4 recruiting. 23 Phase 2, 13 Phase 3, 7 Phase 1, 2 Not applicable, 2 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 223Active not recruiting 7, Completed 5, Unknown 5, Recruiting 3, Not yet recruiting 2, Withdrawn 1
Phase 313Unknown 5, Completed 3, Active not recruiting 2, Enrolling by invitation 1, Recruiting 1, Withdrawn 1
Phase 17Active not recruiting 3, Unknown 3, Not yet recruiting 1
Not applicable2Completed 1, Withdrawn 1
Phase 42Completed 1, Withdrawn 1

Follow R-CHOP protocol: new trials by email Literature Review of R-CHOP protocol trials Research Report on R-CHOP protocol

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL
Celecoxib Combined with R-CHOP, R-CHOP - Diffuse Large B-Cell Lymphoma (DLBCL), CD5 Positive
Phase 2RecruitingSun Yat-sen University602026-03-062026-07-22
Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study
R-CHOP, POLA-R-CHP, Lisaftoclax - Diffuse Large B Cell Lymphoma (DLBCL)
Phase 1 / Phase 2Not yet recruitingSun Yat-sen University1222026-02-282026-02-10
Zanubrutinib, Chidamide, and Rituximab Induction With or Without CHOP Versus R-CHOP in Newly Diagnosed Double-Expressor DLBCL
ZCR-CHOP, R-CHOP - BTK Inhibitors, Histone Deacetylase Inhibitor
Phase 2Not yet recruitingLi Zhiming1282025-06-012025-03-24
Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients(Rocket Trial)
Orelabrutinib Oral Tablet, R-CHOP Protocol - Diffuse Large B Cell Lymphoma (DLBCL)
Phase 2RecruitingSun Yat-sen University392024-11-012024-10-22
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
Surovatamig, R-CHOP, R-CVP - Untreated Follicular Lymphoma
Phase 3RecruitingAstraZeneca10182024-08-072026-10-21
Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial)
Selinexor Oral Tablet [Xpovio], R-CHOP Protocol - Diffuse Large B Cell Lymphoma
Phase 2RecruitingSun Yat-sen University422024-08-012026-02-12
A Multicenter, Prospective, Randomized, Controlled Study of Decitabine in Combination With R-CHOP for Initial Treatment of EBV+ Diffuse Large B-cell Lymphoma
R-CHOP, Decitabine in combination with R-CHOP - Lymphoma, Large-Cell, Diffuse
Phase 3Enrolling by invitationSecond Affiliated Hospital of Nanchang University802024-07-012026-01-16
A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma
Tisagenlecleucel, Lenalidomide and rituximab (R2) in 28-day cycles for up to 12 cycles., Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or prednisolone (R-CHOP) in 21-day cycles for 6 to 8 cycles - Follicular Lymphoma (FL)
Phase 3Active not recruitingNovartis Pharmaceuticals1092023-10-022026-04-17
Selinexor in Combination With R-CHOP Followed by Selinexor Maintenance for Untreated EBV-positive DLBCL Patients
Selinexor, R-CHOP Protocol - EBV-Positive Diffuse Large B-Cell Lymphoma, Nos
Phase 1 / Phase 2UnknownSun Yat-sen University542022-11-012023-12-14
A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma
Orelabrutinib and R-CHOP, R-CHOP - Treatment-naїve Mantle Cell Lymphoma
Phase 3CompletedBeijing InnoCare Pharma Tech Co., Ltd.32021-12-222026-03-31
Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma
Immunochemotherapy regimen: Rituximab-bendamustine (Arm A), Immunochemotherapy regimen: Rituximab-bendamustine (Arm B), Immunochemotherapy regimen: R-CHOP (Arm A) - Follicular Lymphoma
Phase 3Active not recruitingFondazione Italiana Linfomi - ETS6052021-12-012026-06-26
Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL)
R-CHOP, R-CHOP + acalabrutinib - Diffuse Large B Cell Lymphoma
Phase 2Active not recruitingUniversity Hospital Southampton NHS Foundation Trust4532021-10-192026-04-30
Acalabrutinib With R-CHOP in Previously Untreated Mantle Cell Lymphoma
Acalabrutinib, R-CHOP chemotherapy - Mantle Cell Lymphoma
Phase 2Active not recruitingUniversity Health Network, Toronto1052021-03-012026-06-12
To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)
tafasitamab, lenalidomide, parsaclisib - Non Hodgkins Lymphoma, Diffuse Large B-cell Lymphoma
Phase 1 / Phase 2Active not recruitingIncyte Biosciences Japan GK722020-12-152026-10-21
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, rituximab and lenalidomide, rituximab and bendamustine - Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
Phase 1 / Phase 2Active not recruitingGenmab5432020-11-032026-11-03
Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)
Epcoritamab (monotherapy), Epcoritamab, Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma
Phase 1 / Phase 2Active not recruitingGenmab782020-08-202026-11-04
PK Study on Ready-to-Use Injection (VSLI-RTU) 1 Vial & 3 Vial Formulation Marqibo® in Hematological Malignant Patients
Vincristine Sulfate Liposome, CHOP, R-CHOP - Hematologic Diseases
Phase 1UnknownAcrotech Biopharma Inc.562020-08-152020-04-16
Copanlisib in Combination With Rituximab and CHOP Chemotherapy in Patients With Previously Untreated DLBCL
Copanlisib, R-CHOP Chemotherapy - Diffuse Large B Cell Lymphoma
Phase 2CompletedUniversity Hospital Muenster622020-06-192026-07-30
Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma
Toripalimab, Rituximab, R-CHOP Protocol - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma
Phase 1 / Phase 2UnknownHuiqiang Huang1402020-04-242022-04-14
Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma
Pembrolizumab, R-CHOP Protocol - B Cell Lymphoma, Lymphoma
Phase 2Active not recruitingUniversity of Chicago512019-08-292025-06-08

Showing 20 of 42. Sign in to see all of them.

Conditions studied

Lymphoma, Large B-Cell, Diffuse (22)  ·  Lymphoma, Follicular (6)  ·  Lymphoma, Mantle-Cell (6)  ·  Lymphoma, Non-Hodgkin (6)  ·  Lymphoma (5)  ·  Pyloric Stenosis, Hypertrophic (2)  ·  HIV Infections (1)  ·  Hematologic Diseases (1)  ·  Hematologic Neoplasms (1)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (1)  ·  Lymphoma, B-Cell (1)  ·  Lymphoma, B-Cell, Marginal Zone (1)  ·  Lymphoma, Large-Cell, Anaplastic (1)  ·  Nausea (1)  ·  Recurrence (1)

Sponsors

Sun Yat-sen University (5)  ·  European Mantle Cell Lymphoma Network (2)  ·  Fondazione Italiana Linfomi - ETS (2)  ·  Fudan University (2)  ·  Genmab (2)  ·  AHS Cancer Control Alberta (1)  ·  Acrotech Biopharma Inc. (1)  ·  Asan Medical Center (1)  ·  AstraZeneca (1)  ·  Australasian Leukaemia and Lymphoma Group (1)  ·  Beijing InnoCare Pharma Tech Co., Ltd. (1)  ·  CTI BioPharma (1)  ·  Dana-Farber Cancer Institute (1)  ·  Heidelberg University (1)  ·  Huiqiang Huang (1)

Countries

China (14)  ·  Germany (8)  ·  United States (7)  ·  France (6)  ·  Italy (6)  ·  Canada (5)  ·  Poland (5)  ·  Spain (5)  ·  Czechia (4)  ·  Australia (3)  ·  Belgium (3)  ·  Denmark (3)  ·  Japan (3)  ·  Netherlands (3)  ·  South Korea (3)

Top investigators

Andrew Davies (1)  ·  Andrew Grigg, Professor (1)  ·  Anita Kumar, MD (1)  ·  Anthony D. Ho, Ph.D., Prof. (1)  ·  Chan Cheah, MBBS FRACP FRCPA DMSc (1)  ·  Douglas Stewart, M.D. (1)  ·  Fang-Fang Lv (1)  ·  Gabor Jurida, M.D. (1)  ·  Hagop Youssoufian, MD (1)  ·  Hanneke C. Kluin-Nelemans, PhD (1)  ·  Ho-Jin Ho-Jin (1)  ·  Johanna Cornelia Kluin-Nelemans, Prof. Dr. (1)  ·  Jun Zhu, MD (1)  ·  Justin Kline, MD (1)  ·  Martin Dreyling, PhD (1)

Results publications

PMID 20032498, PMID 24687837, PMID 19863177, PMID 20644097, PMID 22873532, PMID 23946328, PMID 25559471, PMID 25596266, PMID 26022239, PMID 27313086, PMID 29095677, PMID 29750632, PMID 30125215, PMID 31710995, PMID 31804876, PMID 32022621, PMID 33928400, PMID 34022150, PMID 34708297, PMID 34788401, PMID 35418080, PMID 36469833, PMID 37992261, PMID 39792928, PMID 40397196, PMID 40453056, PMID 40632620, PMID 40920572, PMID 41563911, PMID 41784015, PMID 42411504, PMID 42541678, PMID 42622258, PMID 42660129

NIH funding

2023 (3), 2015 (1), K01TW009488 (1), R21CA180815 (1)